About Ultromics
Ultromics is a company based in Oxford (United Kingdom) founded in 2017 by Ross Upton and Paul Leeson. Ultromics has raised $115.57 million across 7 funding rounds from investors including University of Oxford, Legal & General and Lightrock. Ultromics operates in a competitive market with competitors including Tricog, Fifth Eye, Rhythm AI, CardioLogs and Ligence, among others.
- Headquarter Oxford, United Kingdom
- Founders Ross Upton, Paul Leeson
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ultromics Limited
- Date of Incorporation 22 Mar, 2017
- Jurisdiction OXFORD, OXFORDSHIRE, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$115.57 M (USD)
in 7 rounds
-
Latest Funding Round
Not available
-
Investors
University of Oxford
& 16 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Ultromics
Unlock access to complete
Unlock access to complete
Funding Insights of Ultromics
Ultromics has successfully raised a total of $115.57M across 7 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ultromics
Ultromics has secured backing from 17 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include University of Oxford, Legal & General and Lightrock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Funding is provided to healthcare startups by corporate-backed BVF.
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Early-stage tech and offline focused VC firm funding companies in the US
|
Locked | Locked | Locked |
Investor details for Ultromics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ultromics
Investment portfolio details for Ultromics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ultromics
Detailed financials for Ultromics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ultromics Comparisons
Peer comparison for Ultromics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ultromics
Ultromics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tricog, Fifth Eye, Rhythm AI, CardioLogs and Ligence, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-powered cardiac diagnostic solutions are provided for care pathways.
|
|
| Locked | Locked | Locked |
An analytics platform for managing hemodynamic instability is provided.
|
|
| Locked | Locked | Locked |
AI-based platform for cardiac disease diagnosis is provided.
|
|
| Locked | Locked | Locked |
Automated ECG interpretation is used for cardiovascular screening.
|
|
| Locked | Locked | Locked |
AI-based 2D echocardiography is provided for heart ultrasound analysis.
|
Detailed competitors of Ultromics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ultromics
Complete news archive for Ultromics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ultromics
Ultromics was founded in 2017.
Ultromics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Ross Upton is the current CEO of Ultromics. They have also founded this company.
Ultromics is a funded company, having raised a total of $115.57M across 7 funding rounds to date.
Ultromics was established in 2017 in Oxford, United Kingdom, within the health technology sector. Software named EchoGo is developed to process echocardiography images and detect cardiovascular conditions. Data points such as structural and functional metrics are extracted from individual scans by its AI engine. Diagnostic precision for coronary heart disease is improved through this automated analysis, supporting clinical workflows in cardiology.
Ultromics's top competitors include Tricog, Fifth Eye and VentriJect.
Ultromics has 17 investors. Key investors include University of Oxford, Legal & General, Lightrock, BVF, and Google Ventures.
The valuation of Ultromics is $49.7M as of Sep 2020.